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AbSTRACT
background. Although oral antidiabetic drugs have 
many beneficial pleiotropic effects, they are not free 
from adverse reactions which may interfere with 
glucose homeostasis. This study aimed to assess the 
effects of oral antidiabetic drugs as add-on-therapy 
to metformin, on the metabolic, cardiac and renal 
determinants. 
Material and methods. A total number of seventy-eight 
type 2 diabetes (T2D) patients who were treated with 
metformin were allocated to add-on-therapy for 12 
weeks, with glimepiride (4 mg/day, n = 26), sitagliptin 
(100 mg/day, n = 28), and canagliflozin (300 mg/day, 
n = 24). Anthropometric measurements, glycemic 
indices, and lipid and renal markers, were determined 
before and after the treatment. 
Results. All of the three treatments significantly de-
creased the glycemic indices, triglyceride-to-glucose 
index, and non-significantly altered the serum uric acid-
to creatinine ratio. Glimepiride significantly increased 
the waist-to-height ratio (0.630 ± 0.057 vs. 0.640 ± 
0.057, P = 0.040), while sitaglipitin and canagliflozin 
significantly decreased it (0.650 ± 0.058 versus 0.640 
± 0.054, p = 0.009, and 0.650 ± 0.041 versus 0.630 ± 
0.044, P < 0.001). Estimated glomerular filtration rate 
calculated using Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) equation (ml/min/1.73 m2) sig-
nificantly declined in patients using glimepiride (109.0 
± 10.4 vs. 103.6 ± 10.9, P = 0.001), and sitagliptin 
(106.1 ± 12.4 vs. 103.3 ± 15.0, P = 0.013). 
Conclusion. Careful selection oral antidiabetic agents 
can protect T2D patients from harmful events, particu-
larly those related to cardiovascular events and renal 
function. (Clin Diabetol 2021; 10; 4: 349–353)
Key words: type 2 diabetes, glimepiride, sitagliptin, 
canagliflozin, waist-to-height ratio, triglyceride-to- 
-glucose index, estimated glomerular filtration rate 
Introduction
Several oral antidiabetic drugs related to different 
categories acting via several mechanisms have been 
introduced for the management of type 2 diabetes 
(T2D). Some of them have pleiotropic effects that are 
either favorable or harmful to the patients. Glimepiride 
is a long-acting sulfonylurea compound and, like other 
sulfonylureas, it can cause episodes of hypoglycemia 
and increase the body weight [1]. It has a beneficial ef-
fect on insulin resistance by producing better glycemic 
control [2]. Several studies highlight a non-harmful 
effect of glimepiride against cardiac diseases, but it 
carried also a higher risk of stroke [3]. It has significant 
unfavorable effects on the renal biomarkers, including 
cystatin C, serum creatinine, glomerular filtration rate, 
and urine albumin-to-creatinine ratio [4]. Canagliflozin 
is a sodium-glucose transporter 2 inhibitor (SGLT-2), 
which is considered a second-line treatment of T2D 
[5]. It is a preferred drug in T2D patients with heart 
failure and/or renal impairment as well as it can be 
combined with drugs acting on the glucagon like 
peptide-1 receptor in patients with atherosclerosis [6]. 
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It acts by inhibiting the renal reabsorption of glucose 
at S1 segment of proximal convoluted tubule, leading 
to excess excretion of urinary glucose and lowering of 
blood glucose [7, 8]. Several clinical studies showed 
its safety in elderly T2D patients with cardiac or renal 
complications. There is evidence that SGLT-2 inhibitors 
showed favorable pleiotropic effects on the cardio-renal 
risk factors, including body weight, glomerular filtration 
rate (GFR), microalbuminuria, and glycated hemoglobin 
[9–11]. Sitagliptin is a dipeptidyl peptidase-4 inhibitor 
that is extensively used in the management of T2D 
with metabolic derangement or cardio-renal risk fac-
tors [12]. In the Sitagliptin Cardiovascular Outcomes 
Study-Cardiovascular Safety trial, sitagliptin therapy 
in T2D patients with established cardiovascular disease 
showed negligible effects on the major adverse cardiac 
events without increased risk of heart failure [13]. Most 
previous studies recommended the abovementioned 
oral antidiabetics with metformin to obtain good 
glycemic control [14–16]. Moreover, T2D per se is a 
cardio-renal risk factor as well as it is a comorbid dis-
ease with cardiac or renal disease. Therefore, this study 
aimed to compare the effects of oral antidiabetic drugs 
belonging to different categories as add-on-therapy to 
metformin on the risk factors related to the metabolic 
derangement as well as cardiac and renal determinants.
Material and methods
Seventy-eight patients with type 2 diabetes already 
treated with metformin participated in this open-label 
clinical trial. The participants were informed about the 
treatment strategies before they signed the consent 
form. The ethics committee of the Hawler Medical 
University approved this study and registered it into the 
records of the clinical trials (No.276). Eligible patients 
were of both sexes aged more than 40 years. The criteria 
of inclusion were T2D patients treated with metformin 
(median dose 2200 mg daily) for variable periods of 
time (median duration is 2 years). 
Participants who had a history of type 1 diabetes, 
latent onset type-1 diabetes, systemic disease (including 
liver, heart, pulmonary, and renal diseases), terminal 
illness, and those using medicines or herbs that act on 
the glucose homeostasis during four preceding weeks, 
pregnancy, nursing mothers, and any history of drug-
hypersensitivity reactions were excluded from the study. 
The sample size was calculated at least 20 patients in 
this study using a-coefficient (type II error) = 0.05, 
b-coefficient (type I error) = 0.2, and power = 85%. 
The patients were randomly allocated for anti-diabetic 
drugs using a random numbers table. 
Group A (26 patients) treated with glimepiride 
tablet (starting with a small dose and then stepwise 
increased to achieve glycemic control at 4mg daily, 
before breakfast.) 
Group B (28 patients) treated with sitagliptin tablet 
(100 mg, before breakfast)
Group C (24 patients) treated with canagliflozin 
tablet (starting with a small dose and then stepwise 
increased to achieve glycemic control at 300 mg daily, 
before breakfast)
Demographic data, a history of metformin therapy, 
signs and symptoms of unfavorable reactions were re-
corded. Each patient was fully examined by consultant 
endocrinologists and the following determinants that 
related to the objective of the study were measured 
before initiation of the study and after 12 weeks of 
treatment with each anti-diabetic drug:
Anthropometric measurements
The weight (kg), height (cm), and waist circumfer-
ence (cm) were measured. The waist-to-height ratio 
(WHtR) was simply calculated by dividing the waist 
(cm) by the height (cm), and a cutoff value of ≥ 0.5 
is a predictor of the cardiometabolic risk factor [17].
Measurements of glycemic indices, lipid profile 
and renal indices: 
Fasting plasma glucose (FPG), glycated hemoglobin 
(HbA1c %), fasting serum triglyceride, serum uric acid 
and creatinine were determined in the Laboratories of 
Layla Qassim Diabetic Center as routine investigations. 
The following determinants were calculated:
Triglyceride-to-glucose index (TYG) = 
fasting serum triglyceride (mg/dL) × fasting plasma 
glucose (mg/dL)
LN                                                                          [18]
2
Serum uric acid-to creatinine ratio (UA/Cr ratio)
Estimated glomerular filtration rate (eGFR) calculated 
using the Chronic Kidney Disease Epidemiology Col-
laboration (CKD-Epi) formula [19]: 
eGFR = 141 × min (Scr/k, 1)a × max (Scr/k, 1)–1.209 × 
× 0.993Age × 1.018 [if female] minus 1.159 [if black], 
where Scr is serum creatinine, k is 0.7 for females and 
0.9 for males, a is –0.329 for females and –0.411 for 
males, min indicates the minimum of Scr/k or 1, and 
max indicates the maximum of Scr/k or 1. 
Statistical analysis
The results are expressed as a number, median, and 
mean ± SD. The data were analyzed using an independ-
ent two-sample two-tailed paired Student’s t-test, and 
Spearman’s correlation test, taking a P-value of ≤ 0.05 
as the lowest limit of significance. Excel 2010 software 
was applied for the statistical analysis.
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Results 
A total of seventy-eight patients allocated to three 
treatment groups completed twelve weeks of treatment 
with regular follow-up. The baseline characteristics of 
the participants are shown in Table 1. It was observed 
that in all three groups the age, duration of T2D, and 
using metformin therapy were insignificantly differ-
ent. Regarding the sex ratio (male-to-female), Group 
B showed a lower ratio compared with Group A and C. 
Table 2 showed that TYG significantly correlated 
with FPG (r = 0.572, P < 0.001), and WHtR (r = 0.304, 
P = 0.007). eGFR significantly correlated with UA/Cr 
ratio (r = 0.342, P = 0.002) and inversely with WHtR 
(–0.272, P = 0.016). In the groups treated with sitaglip-
tin or canagliflozin, there was a significant reduction of 
FPG and WHtR after 12 weeks of treatment compared 
to the corresponding baseline data (Table 3). Canagli-
flozin reduced the FPG by 36.2%, while glimepiride 
and sitagliptin reduced the FPG by 29.7% and 25%, 
respectively. Glimepiride increased the WHtR by 1.6% 
while sitagliptin and canagliflozin reduced the WHtR 
by 1.6% and 3.1%, respectively. A significant reduction 
of eGFR was observed in patients treated with glime-
piride and sitagliptin, which accounted for 5.3% and 
2.6%, respectively. Canagliflozin significantly improved 
the eGFR by 0.5% increment. Table 3 shows that the 
reduction of eGFR was significant in Groups A and B. 
None of the three treatments significantly decreased 
serum UA/Cr ratio. Episodes of hypoglycemia were not 
reported in any treatment group.
Discussion 
In this study, a significant correlation between 
the glycemic index and renal indices with the cardio-
metabolic risk factors represented by WHtR and TYG 
in T2D were observed. In all the three treatments, the 
cardiometabolic risk factors were improved to a certain 
extent while the eGFR was declined in Group A (treat-
ment with glimepiride) and Group B (treatment with 
sitagliptin). This study agreed with previous studies that 
show T2D patients have multi-cardiometabolic risk fac-
tors, including obesity and dyslipidemia. Browning et 
al. reported that WHtR = 0.5 is a predictor of diabetes 
and cardiovascular events in both sexes of the popula-
tion, which indicates that the study patients are at risk 
of developing cardiovascular events [20]. Therefore, 
glimepiride therapy can contribute to the development 
of cardiovascular events in T2D, because it increases 
significantly the WHtR by 1.6% over 12-week treatment 
[21]. Sitagliptin and canagliflozin improved one of the 
risk factors of cardiovascular diseases, which is a sig-
nificant decrease in WHtR [22]. Triglyceride-to-glucose 
index was significantly decreased by using glimepiride, 
sitagliptin, and canagliflozin, but canagliflozin more 
effectively reduced the TYG compared with glimepiride, 
or sitagliptin (8.2% vs. 3.9% and 4.5%). This finding 
agreed with the previous study that showed long term 
therapy of canagliflozin over 52 weeks was highly ef-
fective against the components of metabolic syndrome 
compared with glimepiride and sitagliptin [23]. None 
of the three treatments had a significant effect on the 
serum UA/Cr ratio. A recent study demonstrated that 
sitagliptin increased the serum uric acid level that was 
significantly correlated with HOMA-B, which indicates 
Table 1. baseline data
Variables group A 
glimepride (n = 26)
group b 
Sitagliptin (n = 28)
group C 
Canagliflozin (n = 24)
Age (year) 48.0 48.5 46.5
Sex (Male: Female) 10:16 7:21 11:13
Duration of diabetes (year) 3.25 4 4
Metformin dosage (mg) 2,200 2.200 2,350
Duration of metformin therapy (year) 2.0 2.0 2.25
The results are expressed as median value
Table 2. baseline correlations between fasting serum glu-
cose and metabolic and renal indices 























The results are presented as Spearman’s correlation coefficient. P: prob-
ability, FPG: Fasting plasma glucose, TYG: Triglyceride-glucose index.  
UA/Cr ratio: Serum uric acid-to creatinine ratio, eGFR: Estimated glomerular 
filtration rate calculated using CKD-EPI formula, WHtR: waist-to height ratio
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a link between pancreatic beta-cell function and anti-
hyperglycemic efficacy [24]. Other studies report that 
canagliflozin had dual effects on the serum levels of uric 
acid and this effect depended on the baseline serum 
uric acid level [25]. Canagliflozin improves the serum 
uric acid if the baseline value is low and vice versa [25, 
26]. Therefore, the effect of antidiabetic agents on the 
serum uric acid is variable, despite the fact that there 
is a link between serum uric acid level and the func-
tion of the pancreatic beta-cell. Both glimepiride and 
sitagliptin adversely reduced the renal function, which 
was reflected by the evidence of decreasing the eGFR 
values. This observation agreed with previous work that 
reported sitagliptin can reduce the renal function in 
T2D, but this effect was not associated with cardiovas-
cular outcome events [27]. Previous studies showed that 
glimepiride can impair renal function, while long term 
therapy with canagliflozin slowly reduced the renal func-
tion, which is dose-independent [28]. Thus, slow decline 
of the kidney function during canagliflozin therapy sug-
gests that canagliflozin offered cardiorenal protection 
[29]. Short-term canagliflozin therapy that was applied 
in this study does not show the harmful effect of cana-
gliflozin on the renal function, which is in agreement 
with a study by Takashima et al. who reported a decline 
of eGFR by 0.7 mL/min/1.73 m2 in T2D patients treated 
with canagliflozin for 52 weeks. In brief, anti-diabetic 
agents have multiple pharmacological actions beyond 
their effect on glucose homeostasis. Canagliflozin has 
a favorable effect on the cardiometabolic and renal 
protection indices, while glimepiride has harmful effects 
on cardiovascular risk factors and renal function. The 
strength of the study is using three medications related 
to three different mechanisms of action and using short-
term therapy, which eliminates the confounding factors 
that occur with long term therapy. The most important 
limitation of the study is the small sample size. 
 We conclude that oral antidiabetics are not free 
from adverse reactions that participate in increasing the 
burden of cardiovascular events and renal impairment. 
Careful selection of oral antidiabetic agents can protect 
T2D patients from harmful events.
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